TRACON Pharmaceuticals, Inc. (TCON) Stock: Seeing Gains In Today’s Session


TRACON Pharmaceuticals, Inc. (TCON) is trending up in the market in today’s trading session. The company, focused in the biotech sector, is presently trading at $1.53 after a move up of 2.68% so far today. When it comes to biotech companies, there are a number of aspects that have the potential to generate movement in the market. One of the most common is news. Here are the recent trending headlines surrounding TCON:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-07-19 01:08PM How Should Investors React To TRACON Pharmaceuticals, Inc.s (NASDAQ:TCON) CEO Pay?
Mar-01-19 02:30PM Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT
Feb-28-19 04:02PM TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
02:30PM TRACON Pharmaceuticals, Inc. to Host Earnings Call
Feb-21-19 04:03PM TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019

However, when making a decision to invest, investors should take a look at much more than news, this is especially the case in the speculative biotech industry. Here’s what’s happing when it comes to TRACON Pharmaceuticals, Inc..

Performance Trends That We’ve Seen From TCON

Although a move up on a single session, like the move that we’re seeing from TRACON Pharmaceuticals, Inc. might cause excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always a good idea to look at trends experienced by the stock for a period longer than a single trading session. When it comes to TCON, below are the returns that investors have seen:

  • Past 5 Sessions – In the past seven days, TCON has produced a change in price in the amount of 12.88%.
  • Past Month – The monthly returns from TRACON Pharmaceuticals, Inc. has been 49.00%.
  • Past Three Months – Over the past quarter, the company has produced a return that comes to 34.23%
  • Past 6 Months – Over the previous 6 months, we have seen a change that equates to -33.78% from the stock.
  • Year To Date – Since the open of this year TCON has produced a ROI of 136.51%.
  • Annually – Finally, throughout the past year, we have seen a change amounting to -41.57% out of TCON. Throughout this period of time, the stock has traded at a high price of -52.19% and a low of 206.00%.

Ratios That Are Notable

Looking at a few key ratios associated with a stock can provide traders an understanding of how dangerous and/or rewarding a pick may be. Below are some of the important ratios to look at when digging into TCON.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. As the short ratio goes higher, it shows that more investors believe that the price of the stock is headed for declines. Throughout the sector, biotech stocks tend to have a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, in relation to TRACON Pharmaceuticals, Inc., the stock’s short ratio is 0.94.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure the company’s abilities to pay for its debts when they come due based on quick assets or current assets. Because many biotech companies are reliant on the continuation of investor support, the current and quick ratios can be upsetting. Nonetheless, some gems in the biotechnology space come with strong current and quick ratios. In terms of TCON, the quick and current ratios total up to 3.00 and 3.00 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. as it relates to TRACON Pharmaceuticals, Inc., the book to share value ratio equates to 0.72.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotechnology industry, this is an important ratio to consider. In this case, the cash to share value comes to 1.35.

What Analysts Say About TRACON Pharmaceuticals, Inc.

While it’s not a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their thoughts to validate your own opinions when it comes to making investment decisions in the biotechnology sector. Here are the most recent moves that we’ve seen from analysts as it relates to TCON.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-01-19 Reiterated Needham Buy $7
Jun-13-17 Reiterated Stifel Buy $14 → $6
Dec-21-16 Initiated Jefferies Buy $10
Feb-01-16 Resumed Oppenheimer Outperform
Jul-29-15 Initiated ROTH Capital Buy $18

Big Money And TRACON Pharmaceuticals, Inc.

One thing I’ve come to understand in my short period on Earth has been that good investors tend to follow the moves made by big money players. In other words, investors that are trying to keep the risk down will keep an eye on trades made by institutional investors and insiders of the company. So, how does the big money flow when it comes to TCON? Here’s what’s happening:

Institutions own 67.20% of the company. Institutional interest has moved by 0.18% over the past three months. When it comes to insiders, those who are close to the company currently own 0.40% percent of TCON shares. Institutions have seen ownership changes of an accumulative 84.71% over the last three months.

A Look At Share Counts

Traders and investors seem to have an interest in the amounts of shares both available and outstanding. In terms of TRACON Pharmaceuticals, Inc., there are currently 29.07M and there is a float of 27.24M. These data mean that out of the total of 29.07M shares of TCON that are out there today, 27.24M are able to trade hands on the public market.

I also like to pay attention to the short percent. Think about it, when a large portion of the float is shorted, the overall opinion among investors is that the stock is headed for a dive. When it comes to TCON, the short percentage of the float is currently 1.68%. In general, concerning short percent of the float is anything over 40%. However, I’ve found that any short ratio over 26% is usually a a play that could prove to be very risky.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.43. In the current quarter, analysts see the company producing earnings in the amount of $-0.23. Over the last 5 years, TCON has generated revenue in the amount of $0 with earnings coming in at -14.30%. On a quarter over quarter basis, earnings have seen movement of 30.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was made by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, write a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here